Profound Medical (NASDAQ:PROF; TSX:PRN) has announced that Pejman Ghanouni, MD, PhD, associate professor in the Department of Radiology, Division of Body MRI at Stanford University School of Medicine, has received the Cum Laude award for his presentation titled “CAPTAIN Randomized Controlled Trial of MRI-Guided Transurethral Ultrasound Ablation (TULSA) Versus Robotic Radical Prostatectomy” at the 2025 Radiological Society of North America (RSNA) Annual Meeting, yesterday in Chicago.
RSNA recognizes outstanding education exhibits at its annual meeting with awards of Magna Cum Laude, Cum Laude and Certificate of Merit. Awards are based on review by subspecialty panels within the RSNA Education Exhibits Awards Committee. Dr. Ghanouni’s poster presentation was one of only six that received Cum Laude Awards at RSNA 2025, representing the top 5% of the scientific posters presented at the meeting.
In a statement, Arun Menawat, CEO of Profound, commented, “We would like to congratulate Dr. Ghanouni on receiving the prestigious Cum Laude award from RSNA, a significant professional achievement, as well as a testament to the fact that CAPTAIN enlisted some of the nation’s best academic physicians, which was critical for successful randomization.”
Mr. Menawat added, “To put the perioperative data that Dr. Ghanouni presented into context, robotic RP patients take almost three weeks of recovery on average to feel like TULSA Procedure patients do the very next day after their procedure. To put it another way, the TULSA Procedure is giving more than two weeks back to the patient. We have always known that the TULSA Procedure has no blood loss and no overnight stay with an improved post-treatment patient experience. Now, it is proven with head-to-head Level 1 data. Importantly, these are some of the same metrics that drove patient demand and initial adoption of the surgical robot for prostate cancer many years ago.”
Profound also congratulated Satoru Takahashi, MD, PhD, of Takatsuki General Hospital in Japan, for receiving a Certificate of Merit award from RSNA for his presentation titled “TULSA for Prostate Cancer: MRI-based Pre-treatment Planning and Post-Treatment Assessment – an Emerging Alternative in the Focal Therapy Spectrum”.
The TULSA Procedure is a significant advancement in prostate care. Instead of surgery or radiation, treatment is performed inside an MRI suite using robotically controlled, directional ultrasound to precisely ablate prostate tissue while protecting surrounding structures. TULSA-PRO is the only AI-powered, MRI-guided robotic system for prostate therapy, enabling real-time MRI thermography and autonomous temperature control. This allows physicians to see, monitor and adjust treatment throughout the procedure—delivering personalized therapy with exceptional precision.
